Trial data showed Ocrevus treatment slowed disability progression in PPMS, including patients who were older and had more ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ...
By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...
Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.
US FDA reviews a petition to revoke approval of Roche’s top-selling drug ocrelizumab to treat primary progressive multiple sclerosis: Bristol, UK Thursday, April 16, 2026, 15:00 ...
Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present efficacy data ...
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...
PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...
The oral BTK inhibitor race in RMS is now a two-horse affair, with fenebrutinib vying against Novartis' remibrutinib, already ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results